Diabetic Kidney Disease (Diabetic Nephropathy)

Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a serious complication of diabetes mellitus and the leading cause of end-stage renal disease (ESRD) worldwide. Approximately 30-40% of patients with Type 1 diabetes and 20-40% of patients with Type 2 diabetes will develop some degree of kidney damage over their lifetime. DKD is characterized by progressive albuminuria (protein in the urine), declining glomerular filtration rate (GFR), and increasing risk of cardiovascular complications. The pathophysiology of DKD involves multiple mechanisms including chronic hyperglycemia-induced glycosylation of proteins, oxidative stress, inflammation, and activation of the renin-angiotensin-aldosterone system (RAAS). These processes damage the glomerular basement membrane, mesangial cells, and podocytes, leading to thickening of the glomerular basement membrane, mesangial expansion, and eventually glomerulosclerosis. The disease typically progresses through stages: from hyperfiltration (increased GFR) to microalbuminuria (30-300 mg/day albumin), macroalbuminuria (more than 300 mg/day), and finally declining GFR with progressive kidney failure. Early detection and aggressive management are crucial for slowing the progression of DKD. The cornerstone of treatment includes strict glycemic control (HbA1c below 7%), blood pressure management (target below 130/80 mmHg), and the use of nephroprotective medications. SGLT2 inhibitors (empagliflozin, dapagliflozin) and finerenone have emerged as transformative therapies that significantly slow the progression of DKD independent of glycemic control. Regular screening with urine albumin-to-creatinine ratio (UACR) and eGFR measurements is essential for early detection in diabetic patients.